EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigating the Cellular Effects of GALC Dosing in Enzyme Replacement Therapy for Krabbe Disease Supports the Role of Nanomedicine

Ambra Del Grosso iD, Sara Carpi iD, Laura Colagiorgio iD, Miriam De Sarlo iD, Mariacristina Gagliardi iD, Marco Cecchini iD

Advanced Biology · 2025-09 · 9 (9)

DOI: 10.1002/adbi.202500147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Biology, 2025-07. Verfasst von Ambra Del Grosso und 5 weiteren Autor:innen. Beteiligte Einrichtung: Istituto Nanoscienze - CNR, Pisa, Piazza San Silvestro 12, Pisa, 56127, Italy. Hauptthemen laut MEDLINE: Leukodystrophy, Globoid Cell, Enzyme Replacement Therapy, Galactosylceramidase, Nanomedicine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research, Preclinical testing of single and combined autophagy modulation by Lithium and Rapamycin in Globoid Cell Leukodystrophy, Association Européenne contre les Leucodystrophies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Krabbe disease (KD) is a lysosomal storage disorder characterized by severe neurodegeneration and demyelination. It is caused by mutations in the galactosylceramidase (GALC) gene, leading to the accumulation of psychosine, a neurotoxic metabolite. This study presents an optimized workflow for the production and characterization of recombinant murine GALC (rm‐GALC) from HEK293T cells, aiming to improve the feasibility of enzyme replacement therapy (ERT) for KD. An affinity chromatography protocol is refined to purify His‐tagged rm‐GALC, followed by buffer exchange and concentration steps to produce a stable and active enzyme suitable for subsequent in vitro applications. The purified rm‐GALC is characterized for enzymatic activity, purity, and stability using SDS‐PAGE, immunoblotting, and dynamic light scattering (DLS). In vitro assays reveal dose‐dependent enzymatic activity recovery in KD primary cells upon rm‐GALC administration, with no adverse effects on cell viability up to the physiological GALC dose. Additionally, GALC treatment at the physiological dose restored autophagic function in KD cells, as shown by LC3 and p62 marker analyses, confirming its compatibility with lysosomal‐autophagic pathways. Conversely, supra‐physiological GALC administration resulted in decreased viability and autophagy impairment. Finally, the feasibility of loading GALC into a polymeric nanovector based on stabilized reverse micelles is investigated. These findings highlight the critical importance of precise GALC dose regulation in developing a safe and effective enzyme replacement therapy (ERT) strategy for Krabbe disease (KD), further supporting the potential of a nanovector‐mediated ERT approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukodystrophy, Globoid CellEnzyme Replacement TherapyGalactosylceramidaseNanomedicineHumansAnimalsMiceHEK293 CellsRecombinant ProteinsAutophagy

Stichwörter der Autor:innen

Krabbe diseaseTwitcher mouseautophagy modulationenzyme replacement therapyeukaryotic recombinant enzymes purificationgalactosylceramidase (GALC)globoid cell leukodystrophynanomedicine

Substanzen

GalactosylceramidaseRecombinant Proteins

Autor:innen und Institutionen

  • Istituto Nanoscienze - CNR, Pisa, Piazza San Silvestro 12, Pisa, 56127, Italy.
  • Laboratorio NEST, Scuola Normale Superiore, Piazza S. Silvestro 12, Pisa, 56127, Italy.
  • Department of Health Sciences, University 'Magna Græcia' of Catanzaro, Catanzaro, 88100, Italy.

ORCID-Profile: Ambra Del Grosso, Sara Carpi, Laura Colagiorgio, Miriam De Sarlo, Mariacristina Gagliardi, Marco Cecchini

Förderung

  • Italian Ministry of University and Research
  • Preclinical testing of single and combined autophagy modulation by Lithium and Rapamycin in Globoid Cell Leukodystrophy
  • Association Européenne contre les Leucodystrophies
  • Regione Toscana: Bando Ricerca Salute 2018, project DEM AGING

Zitieren

APA

Del Grosso, A., Carpi, S., Colagiorgio, L., De Sarlo, M., Gagliardi, M., & Cecchini, M. (2025). Investigating the Cellular Effects of GALC Dosing in Enzyme Replacement Therapy for Krabbe Disease Supports the Role of Nanomedicine. Advanced Biology, 9(9). https://doi.org/10.1002/adbi.202500147

Vancouver

Del Grosso A, Carpi S, Colagiorgio L, De Sarlo M, Gagliardi M, Cecchini M. Investigating the Cellular Effects of GALC Dosing in Enzyme Replacement Therapy for Krabbe Disease Supports the Role of Nanomedicine. Advanced Biology. 2025;9(9). doi:10.1002/adbi.202500147

BibTeX
@article{DelGrosso2025,
  author = {Del Grosso, Ambra and Carpi, Sara and Colagiorgio, Laura and De Sarlo, Miriam and Gagliardi, Mariacristina and Cecchini, Marco},
  title = {Investigating the Cellular Effects of GALC Dosing in Enzyme Replacement Therapy for Krabbe Disease Supports the Role of Nanomedicine},
  journal = {Advanced Biology},
  year = {2025},
  volume = {9},
  number = {9},
  doi = {10.1002/adbi.202500147}
}
Kostenlos starten →